Dutasteride — $0 with Membership
Dutasteride has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.
Dutasteride Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 with membership |
| Typical Retail | $89.99 |
Free with membership subject to the listed formulary limits.
About Dutasteride
Dutasteride is a prescription medication. Ask your doctor if Dutasteride is right for you.
Combination products containing Dutasteride
Conditions Treated with Dutasteride
How to Check Dutasteride Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Dutasteride at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Benign Prostatic Hyperplasia
Other medications in Urology
What Dutasteride is approved for (FDA label)
Dutasteride is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: ( 1.1 ) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery.
Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Dutasteride (FDA label)
0.5-mg, yellow to pale yellow colored oblong shaped soft gelatin capsules containing clear oily liquid imprinted with '0.5' in red ink. 0.5-mg soft gelatin capsules (3)
Source: FDA prescribing information (DailyMed). Set ID: c78d18cf-05df-4154-b2f9-39cc374ca9e3. SPL document ID: 5a02c220-eebe-ba1b-e063-6394a90af2bc. Label effective date: August 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Dutasteride (FDA label)
The most common adverse reactions, reported in ≥1% of subjects treated with dutasteride and more commonly than in subjects treated with placebo, are impotence, decreased libido, ejaculation disorders, and breast disorders. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Strides Pharma, Inc. at 1-877-244-9825 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trial of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: c78d18cf-05df-4154-b2f9-39cc374ca9e3. SPL document ID: 5a02c220-eebe-ba1b-e063-6394a90af2bc. Label effective date: August 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Dutasteride (FDA label)
Pregnancy. Dutasteride use is contraindicated in women who are pregnant. (4, 5.4, 8.1) Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride capsules or other 5 alpha-reductase inhibitors. (4) Dutasteride is contraindicated for use in: Pregnancy. Dutasteride use is contraindicated in women who are pregnant. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, dutasteride may cause fetal harm when administered to a pregnant woman [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)] . Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2)] .
Source: FDA prescribing information (DailyMed). Set ID: c78d18cf-05df-4154-b2f9-39cc374ca9e3. SPL document ID: 5a02c220-eebe-ba1b-e063-6394a90af2bc. Label effective date: August 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Dutasteride (FDA label)
Dutasteride reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on dutasteride capsules may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. ( 5.1 ) Dutasteride may increase the risk of high-grade prostate cancer. ( 5.2 , 6.1 ) Prior to initiating treatment with dutasteride capsules, consideration should be given to other urological conditions that may cause similar symptoms. ( 5.3 ) Women who are pregnant or may be pregnant should not handle dutasteride capsules due to potential risk to a male fetus. ( 5.4 , 8.1 ) Patients should not donate blood until 6 months after their last dose of dutasteride. ( 5.5 ) 5.1 Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection In clinical trials, dutasteride reduced serum PSA concentration by approximately 50% within 3 to 6 months of treatment.
Source: FDA prescribing information (DailyMed). Set ID: c78d18cf-05df-4154-b2f9-39cc374ca9e3. SPL document ID: 5a02c220-eebe-ba1b-e063-6394a90af2bc. Label effective date: August 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Dutasteride (FDA label)
Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). ( 7 ) 7.1 Cytochrome P450 3A Inhibitors Dutasteride is extensively metabolized in humans by the cytochrome P450 (CYP)3A4 and CYP3A5 isoenzymes. The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing dutasteride capsules to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) [see Clinical Pharmacology ( 12.3 )] . 7.2 Alpha-adrenergic Antagonists The administration of dutasteride in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated. 7.3 Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. The change in dutasteride exposure is not considered to be clinically significant.
Source: FDA prescribing information (DailyMed). Set ID: c78d18cf-05df-4154-b2f9-39cc374ca9e3. SPL document ID: 5a02c220-eebe-ba1b-e063-6394a90af2bc. Label effective date: August 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.